Selective immunotherapy of small cell cancer xenografts using 131I-labelled SWA11 antibody.

por Smith, A., Waibel, R., Stahel, R. A.
Publicado 1991

Clinical and immune modulatory effects of alternative weekly interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma and melanoma.

por Pichert, G., Jost, L. M., Fierz, W., Stahel, R. A.
Publicado 1991

Autocrine stimulation of a human lung mesothelioma cell line is mediated through the transforming growth factor alpha/epidermal growth factor receptor mitogenic pathway.

por Mórocz, I. A., Schmitter, D., Lauber, B., Stahel, R. A.
Publicado 1994

Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines.

por Zangemeister-Wittke, U., Schenker, T., Luedke, G. H., Stahel, R. A.
Publicado 1998

Expression of the small cell carcinoma antigens of cluster-5 and cluster-5A in primary lung tumours.

por Maier, A., Schmidt, U., Waibel, R., Hartung, W., Stahel, R. A.
Publicado 1989

Potent cytotoxic action of the immunotoxin SWA11-ricin A chain against human small cell lung cancer cell lines.

por Derbyshire, E. J., Henry, R. V., Stahel, R. A., Wawrzynczak, E. J.
Publicado 1992

Immunolocalisation and imaging of small cell cancer xenografts by the IgG2a monoclonal antibody SWA11.

por Smith, A., Waibel, R., Westera, G., Martin, A., Zimmerman, A. T., Stahel, R. A.
Publicado 1989

Immunotoxins recognising a new epitope on the neural cell adhesion molecule have potent cytotoxic effects against small cell lung cancer.

por Zangemeister-Wittke, U., Collinson, A. R., Frösch, B., Waibel, R., Schenker, T., Stahel, R. A.
Publicado 1994

Thyroiditis after treatment with interleukin-2 and interferon alpha-2a.

por Pichert, G., Jost, L. M., Zöbeli, L., Odermatt, B., Pedia, G., Stahel, R. A.
Publicado 1990

Biodistribution and tumour localisation of 131I SWA11 recognising the cluster w4 antigen in patients with small cell lung cancer.

por Ledermann, J. A., Marston, N. J., Stahel, R. A., Waibel, R., Buscombe, J. R., Ell, P. J.
Publicado 1993

Inhibition of autophagy sensitizes malignant pleural mesothelioma cells to dual PI3K/mTOR inhibitors

por Echeverry, N, Ziltener, G, Barbone, D, Weder, W, Stahel, R A, Broaddus, V C, Felley-Bosco, E
Publicado 2015

Final report of a phase II study of interleukin 2 and interferon alpha in patients with metastatic melanoma.

por Kruit, W. H., Goey, S. H., Calabresi, F., Lindemann, A., Stahel, R. A., Poliwoda, H., Osterwalder, B., Stoter, G.
Publicado 1995

Selective cytotoxic effects of a ricin A chain immunotoxin made with the monoclonal antibody SWA11 recognising a human small cell lung cancer antigen.

por Wawrzynczak, E. J., Derbyshire, E. J., Henry, R. V., Parnell, G. D., Smith, A., Waibel, R., Stahel, R. A.
Publicado 1990

Assessing standardization of molecular testing for non-small-cell lung cancer: results of a worldwide external quality assessment (EQA) scheme for EGFR mutation testing

por Patton, S, Normanno, N, Blackhall, F, Murray, S, Kerr, K M, Dietel, M, Filipits, M, Benlloch, S, Popat, S, Stahel, R, Thunnissen, E
Publicado 2014

The selection of antibodies for targeted therapy of small-cell lung cancer (SCLC) using a human tumour spheroid model to compare the uptake of cluster 1 and cluster w4 antibodies.

por Olabiran, Y., Ledermann, J. A., Marston, N. J., Boxer, G. M., Hicks, R., Souhami, R. L., Spiro, S. G., Stahel, R. A.
Publicado 1994

Initial prognostic factors in small-cell lung cancer patients predicting quality of life during chemotherapy. Swiss Group for Clinical Cancer Research (SAKK).

por Bernhard, J., Hürny, C., Bacchi, M., Joss, R. A., Cavalli, F., Senn, H. J., Leyvraz, S., Stahel, R., Ludwig, C., Alberto, P.
Publicado 1996

Molecular and biological properties of an abrin A chain immunotoxin designed for therapy of human small cell lung cancer.

por Wawrzynczak, E. J., Zangemeister-Wittke, U., Waibel, R., Henry, R. V., Parnell, G. D., Cumber, A. J., Jones, M., Stahel, R. A.
Publicado 1992

Lessons from the ‘Iressa’ Expanded Access Programme: gefitinib in special non-small-cell lung cancer patient populations

por Stahel, R, Rossi, A, Petruzelka, L, Kosimidis, P, de Braud, F, Bernardo, M M, Souquet, P-J, Parra, H Soto, Gridelli, C
Publicado 2003

CD74: a new prognostic factor for patients with malignant pleural mesothelioma

por Otterstrom, C, Soltermann, A, Opitz, I, Felley-Bosco, E, Weder, W, Stahel, R A, Triponez, F, Robert, J H, Serre-Beinier, V
Publicado 2014

Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial

por Girard, N., Ponce Aix, S., Cedres, S., Berghmans, T., Burgers, S., Toffart, A.-C., Popat, S., Janssens, A., Gervais, R., Hochstenbag, M., Silva, M., Burger, I.A., Prosch, H., Stahel, R., Xenophontos, E., Pretzenbaher, Y., Neven, A., Peters, S.
Publicado 2023